

10030846 071902

10/030846

531 Rec'd PCT/PT 11 JAN 2002

S/N unknown

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: LAROSE et al. Serial No.: unknown  
Filed: concurrent herewith Docket No.: 9555.127USWO  
Title: METHOD FOR NORMALIZING THE RELATIVE INTENSITIES OF  
DETECTION SIGNALS IN HYBRIDIZATION ARRAYS

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EV036335978US

Date of Deposit: 11 January 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By: 

Name: Chris Stordahl

PRELIMINARY AMENDMENT

Box PCT  
Assistant Commissioner for Patents  
Washington, D. C. 20231

Dear Sir:

In connection with the above-identified application filed herewith, please enter the following preliminary amendment.

IN THE SPECIFICATION

A courtesy copy of the present specification is enclosed herewith. However, the World Intellectual Property Office (WIPO) copy should be relied upon if it is already in the U.S. Patent Office.

IN THE CLAIMS

Please amend claims 4 and 6-9 as follows:

4. (Amended) A method as defined in claim 1, further comprising:  
  
determining the quantity of hybridized rRNA-derived cDNA.

6. (Amended) A method as described in claim 1, wherein said rRNA competitor probe is present in a concentration that is about 5 to about 100 times that of the rRNA-cDNA probe.
7. (Amended) A method as described in claim 1, wherein said rRNA-derived cDNA is labeled by 3' addition of phosphate, cyanines, biotin, digoxigenin, florescein, a dideoxynucleotide, an amine, a thiol, an azo (N<sub>3</sub>) group, fluorine, or any other form of label.
8. (Amended) A method as described in claim 1, which is used in high-throughput screening.
9. (Amended) A method as described in claim 1, wherein said array experiment consists in the identification of sequences found in the open reading frame of genes coding for transcription factors.

REMARKS

The above preliminary amendment is made to remove multiple dependencies from claims 4 and 6-9.

Applicants respectfully request that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.


If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicants' primary attorney-of record, Gregory A. Sebald (Reg. No. 33,280), at (612) 3363.4728.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: 11 January 2002

By

  
Gregory A. Sebald  
Reg. No. 33,280

GAS:hjh

10/030846

531 Rec'd PCT/PTC 11 JAN 2002

9555.127USWO

## MARKED-UP COPY

4. A method as defined in [any one of claims 1 to 3,] claim 1, further comprising:  
determining the quantity of hybridized rRNA-derived cDNA.
6. A method as described in [any one of claims 1 to 5,] claim 1, wherein said rRNA competitor probe is present in a concentration that is about 5 to about 100 times that of the rRNA-cDNA probe.
7. A method as described in [any one of claims 1 to 6,] claim 1, wherein said rRNA-derived cDNA is labeled by 3' addition of phosphate, cyanines, biotin, digoxigenin, fluorescein, a dideoxynucleotide, an amine, a thiol, an azo (N<sub>3</sub>) group, fluorine, or any other form of label.
8. A method as described in [any one of claims 1 to 7,] claim 1, which is used in high-throughput screening.
9. A method as described in [any one of claims 1 to 8,] claim 1, wherein said array experiment consists in the identification of sequences found in the open reading frame of genes coding for transcription factors.